Logo
x

Search

Subscribe Now

Novocure

Novocure Reports CE Mark Approval of Optune Lua for Metastatic NSCLC (mNSCLC)

Novocure Reports CE Mark Approval of Optune Lua for Metastatic NSCLC (mNSCLC)

  • April 22, 2025
Novocure’s Optune Lua Receives the US FDA’s Nod for Treating Metastatic Non-Small Cell Lung Cancer

Novocure’s Optune Lua Receives the US FDA’s Nod for Treating Metastatic Non-Small Cell Lung Cancer

  • October 16, 2024
Novocure Reports Data from the P-III (METIS) Study of Stereotactic Radiosurgery in NSCLC Patients

Novocure Reports Data from the P-III (METIS) Study of Stereotactic Radiosurgery in NSCLC Patients

  • March 28, 2024
PharmaShots Weekly Snapshots (January 02 - 06, 2023)

PharmaShots Weekly Snapshots (January 02 - 06, 2023)

  • January 6, 2023
Novocure Reports Results from P-III Pivotal Study of Tumor Treating Fields in Non-Small Cell Lung Cancer

Novocure Reports Results from P-III Pivotal Study of Tumor Treating Fields in Non-Small Cell Lung Cancer

  • January 6, 2023
PharmaShots Interview: Novocure's William F. Doyle Shares Insight on Company's Accomplishments in the Treatment of Glioblastoma and Mesothelioma

PharmaShots Interview: Novocure's William F. Doyle Shares Insight on Company's Accomplishments in the Treatment of Glioblastoma an...

  • December 9, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.